Pramodini Medicare IPO
Live SMEAlready have an account? Apply now
Pramodini Medicare IPO details
Schedule of Pramodini Medicare
| Issue open date | 12 Aug 2026 |
| Issue close date | 14 Aug 2026 |
| UPI mandate deadline | 14 Aug 2026 (5 PM) |
| Allotment finalization | 17 Aug 2026 |
| Refund initiation | 18 Aug 2026 |
| Share credit | 18 Aug 2026 |
| Listing date | 19 Aug 2026 |
| Mandate end date | 29 Aug 2026 |
| Lock-in end date for anchor investors (50%) | 15 Sep 2026 |
| Lock-in end date for anchor investors (remaining) | 14 Nov 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Pramodini Medicare
Pramodini Medicare Limited is an Indian diagnostic service provider offering a comprehensive range of technology-enabled services, including radiology, clinical laboratory testing, and nuclear medicine. The company serves public and private hospitals, government Public Sector Undertakings (PSUs), and medical colleges across tier I, II, and III cities. Its core offerings are divided into three segments: Radiology (MRI, CT scans, ultrasound), Clinical Laboratory (pathology, microbiology, immunology), and Nuclear Medicine (PET-CT and nuclear therapy). Additionally, it operates a 24×7 teleradiology service from its registered office in Vijayawada. Pramodini Medicare generates revenue by providing routine and specialized tests for prediction, early detection, and disease monitoring. The business uniquely operates across four key models: Public-Private Partnerships (PPP) with government hospitals, Private-Private Partnerships, strategic alliances with PSUs, and standalone private centres. This diversified approach enables the company to deliver widespread preventative and diagnostic healthcare solutions across India.
Financials of Pramodini Medicare
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 69.04 |
| Fresh Issue – Proceeds go to the company | 63.14 |
| Offer for sale – Proceeds go to the existing investors | 5.90 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Capex for medical equipment at existing and proposed centres | 45.15 (71.51%) |
| General corporate purposes and inorganic acquisitions | 17.99 (28.49%) |
Strengths
- The business model spans PPP, private hospitals, PSUs, and standalone centres.
- The diagnostic network grew from 1 centre in FY15 to 16 centres today.
- Offers specialized services across radiology, clinical laboratory, and nuclear medicine.
- Revenue grew significantly from ₹3,522.95 lakhs in FY24 to ₹6,228.75 lakhs in FY26.
- Leverages public health infrastructure through extensive government MOUs.
Risks
- High dependence on government PPP MOUs subject to non-renewal or delayed payments.
- Focus on capital-intensive radiology exposes the firm to equipment and regulatory risks.
- Over 60% revenue concentration in Andhra Pradesh creates geographic risk.
- Loss of top institutional clients could severely impair revenue and profitability.
- Past statutory filing delays and non-compliances expose the firm to regulatory penalties.